The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly | Zendy

John S. Bevan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly

Author(s) -

John S. Bevan

Publication year - 2005

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2004-1093

Subject(s) - acromegaly , somatostatin , medicine , endocrinology , medical therapy , octreotide , oncology , growth hormone , hormone

Somatostatin analogs are the mainstay of medical therapy for acromegaly. Suppression of GH hypersecretion, lowering of IGF-I production, and control of symptoms are established benefits of therapy. In addition, clinically significant tumor shrinkage has been seen in a number of studies, particularly in patients undergoing primary medical therapy. This review summarizes current knowledge of the effects of somatostatin analogs on tumor size and cellular morphology and examines the available data on predictors of tumor shrinkage.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research